19 Mar 2007 - Angiotech Pharmaceuticals, Inc. announced a favourable decision regarding its Hunter Patent from the European Patent Office (EPO) in Munich, Germany.
The EPO's Technical Board of Appeal rejected the attempt by Conor Medsystems Inc. and Sahajanand Medical Technologies Pvt. Ltd. to intervene and appeal an earlier decision by the Opposition Division of the European Patent Office, which upheld the Hunter patent. The decision found that these appeals were "inadmissible."
"We are pleased with the EPO's decision, and Angiotech views this outcome as yet another confirmation of the strength and validity of our patent portfolio," said Dr. William Hunter, President and CEO of Angiotech.
 |
www.bionity.com/news/e/62827 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/62827 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |